HERAMED LIMITED(HMD)

The suspension of trading in the securities of HeraMED Limited will be lifted from the commencement of trading today, 5 August 2025, following lodgement of its quarterly activity report and quarterly cash flow report for the quarter ended 30 June 2025 and announcement in relation to a material capital raising.

The company lodges its quarterly activities and cashflow report.

The company has completed a $1.98 million private placement, attracting strong support from institutional and sophisticated investors. The proceeds will provide working capital for near-term commercial opportunities in the U.S., Australia, and Europe.

The company's securities will be suspended from quotation under Listing Rule 17.5 from 1 August 2025 due to not filing a periodic report by the due date. If lodged between market announcements office closure on 31 July 2025 and suspension, securities will be reinstated on the next trading day.

The suspension of trading in the securities of HeraMED Limited will be lifted from the commencement of trading today, following lodgement of its outstanding quarterly cash flow and activities report and announcement relating to its capital raise and restructure.

Strategic review resulting in a clearly defined Strategic Plan, streamlined operations, cost optimisation and successful capital raising; Completion of successful capital raising totalling $2.75m before costs; Rationalisation of operations and centralising of administrative and governance functions estimated to reduce the operating cost base, on an annualised basis, by approximately $2.0 million; and Management focusing on pipeline opportunities in target markets with clarity on key commercialisation opportunities and strategic priorities.

The company lodges its Quarterly Activities and Cashflow Report.

The company releases a notice of proposed issue of securities.

The company requests a further extension of its securities, effective from trading on 9 May 2024, and to remain in voluntary suspension until 13 May 2024 or when an announcement regarding proposed financing and Board changes is released. HeraMED is actively engaged with third parties to finalize additional funding, but it believes continued trading could materially prejudice its ability to complete the additional funding and resolve any Board changes.

The company announces that the Australian Securities and Investment Commission (ASIC) has granted an extension to the company's Annual General Meeting AGM to 20 June 2024, in accordance with section 250P of the Corporations Act 2001. The AGM will be held at 20 June 2024, allowing shareholders to consider and vote on critical matters at a single meeting. The AGM Notice of Meeting, released on 30 April 2024, will be replaced by an updated Notice of Meeting, with details of the time and venue to be announced in a formal Notice of Meeting. For any questions about the extension, shareholders can contact CFO & Company Secretary Cameron Jones.

The company will hold its annual general meeting at 10.30am (AEST) on 30 May 2024 at BDO Offices, Tower 4, Level 18/727 Collins Street, Docklands VIC 3008.

The Company requests its securities to remain in voluntary suspension until 9 May 2024 or when an announcement regarding proposed financing and Board changes is released, as continued trading may hinder discussions with third parties.

The Company requests that its securities remain in voluntary suspension until the earlier of 9 May 2024 or when the Company releases an announcement in relation to a proposed financing and Board changes.

The company releases a response to ASX Appendix 3Y Query.

HeraMED Limited advises that the Annual General Meeting of the Company is intended to be held on Thursday 30 May 2024. Any person wishing to be considered for election as a director must provide their nomination to the Company, which must be received at the Company's registered office no later than 5.00pm (AEST) on Wednesday, 17 April 2024.

As outlined in ASX announcement titled Supplemental information "“ Voluntary Suspension on 8 April 2024, the Company requests that the suspension remains in place until the Company releases an announcement in relation to the restructure of the business, the financial position of the Company, associated capital requirements and proposed financing to fund ongoing operations of the business. The discussions referred to above are ongoing, and at this stage it is difficult to predict a timetable for their conclusion however the Company is working to finalise the above matters urgently and currently intends to make that announcement by 29 April 2024. Further updates will be provided in due course.

The company releases supplemental information regarding the suspension of its securities. The Company is actively engaged with third parties to secure additional funding. Successful completion of additional funding is critical to the Company's continued financial viability. In connection with seeking to secure further funding, the Company is reviewing the structure of its business operations and associated capital requirements. In the Company's opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with third partiesto secure additional funding and to resolve the nature and extent of changes to it Director and Management.

The company releases supplemental information regarding the suspension of its securities. The Company is actively engaged with third parties to secure additional funding. Successful completion of additional funding is critical to the Company's continued financial viability. In connection with seeking to secure further funding, the Company is reviewing the structure of its business operations and associated capital requirements. In the Company's opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with third partiesto secure additional funding and to resolve the nature and extent of changes to it Director and Management.

The securities of HeraMED Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding changes in Directors and Management, the restructure of the business, associated capital requirements and proposed financing to fund ongoing operations of the business which is critical to the Company's financial viability.

The securities of HeraMED Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding changes in Directors and Management, the restructure of the business, associated capital requirements and proposed financing to fund ongoing operations of the business which is critical to the Company's financial viability.

The suspension of trading in the securities of HeraMED Limited will be lifted immediately following the release by HMD of an announcement regarding a material contract.

Broward Health is one of the 10 largest public healthcare systems in the US and includes five hospitals, across more than 50 locations and offices, and a team of over 1,800 nationally recognised doctors; Broward Health has signed a two-year agreement for adoption of the HeraCARE platform, beginning with 700 HeraCARE licenses and 200 bundles of hardware (including HeraBEAT devices), representing the largest deployment in USA to date; Broward Health will pay HeraMED US$99,600 up front for 200 bundles (each bundle to include a HeraBEAT, Blood Pressure Cuff, Bluetooth Scales, and a co-branded Diaper bags). Broward Health will also pay US$100,400 in advance in each of the next two years, for up to 700 active licenses; There is an option for Broward to purchase another 200 bundles for US$99,600 at any point during the two years. And if Broward exercise this option, then the total consideration would be approximately US$400,000 over the two years representing.

The securities of Heramed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, in relation to an announcement to the market regarding a material new contract.

The suspension of trading in the securities of HeraMED Limited will be lifted immediately following the release by HMD of an announcement regarding an Australian based commercial licence agreement for the rollout of the HeraCARE solution.

● Joondalup Health Campus (JHC) has entered into a full-scale long-term commercial agreement with medical data and technology company HeraMED to adopt the complete HeraCARE solution as the primary standard of care offered for their audience of expecting mothers. Commercial terms reached under the paid pilot agreement, including the SaaS fees, will extend for 12 months, with both parties exploring extension of the contract for a further three years. The contract value for the first 12 months is expected to be approximately A$220,000. HMD will progressively deliver HeraCARE SaaS licences (including the HeraBEAT smart foetal monitors) to support JHC's services expansion. This is the first major Healthcare group to adopt the comprehensive HeraCARE virtual and remote monitoring solution as part of their innovative care model for pregnant mothers. This agreement validates HeraMED's commercialisation strategy undertaking clinical trials leading to paid pilots and then ultimately full commercial deployment within a leading hospital group. JHC (part of Ramsay Health Care) is one of Western Australia's largest hospitals, a leading medical institution, and a maternity care service provider to an average of 3,000 expectant mothers annually.

The securities of HeraMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding an Australian based commercial licence agreement for the roll-out of the HeraCARE solution.

The suspension of trading in the securities of HeraMED Limited will be lifted immediately, following the release by HMD of an announcement regarding finalising a material collaboration agreement.

The company releases a notice of Proposed issue of Securities - HMD.

The company is extending its collaboration with Mayo Clinic with a new agreement for the development of its HeraCARE pregnancy management platform that includes an equity investment to support the project.

The securities of HeraMED Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding finalising a material collaboration agreement.

listed entity carried for record purposes only